News

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

X-ray-triggered liposomes deliver precisely controlled cancer treatment

Combining chemotherapy and radiotherapy would be ideal for cancer treatment, but administering both at the same time can lead to unacceptable and often deadly levels of toxicity. Now researchers have developed liposomes that contain a chemotherapy drug activated by radiotherapy, offering both cancer-killing power and a targeted approach in a more controlled manner.

Drug delivery specialist Genisphere receives an additional $2M in funding

Drug delivery specialist Genisphere announced that it has raised $2 million in private funding to advance its 3DNA nanotechnology platform through collaborations with pharma companies. The funders are existing investors including Corporate Fuel Partners.

Market research firm: RNA-based drugs to exceed $1B in sales by 2020

Market research firm Allied Market Research forecasts that RNA-based therapies will generate $1.2 billion in revenue by 2020, a compounded annual growth rate of 28.4%, according to a recent report.

Novaliq dissolvable drops improve eye quality in clinical trials

Drug delivery company Novaliq GmbH today announced that its clinical stage NovaTears OTC eye drops showed promise in patients with mild to moderate evaporative dry eye disease.

Low T products under FDA scrutiny over safety concerns

"Low T" products are characterized by a variety of different drug delivery technologies and mechanisms. In May, the FDA approved the first nasal gel for low testosterone. And in March, the agency finally approved Aveed as an injection given once to begin therapy, once four weeks later, and every 10 weeks after that.

Microneedle patch delivers painkiller to second layer of skin in 5 minutes

Researchers in Singapore have developed a microneedle patch capable of delivering the painkiller lidocaine with just 5 minutes of application, a far cry from the 45 minutes they say is required of those commercially available now.

HIV-fighting intravaginal ring research nets $20M from NIH

The U.S. National Institutes of Health devoted $20 million to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.

Seaweed-based suppository shows promise delivering antiretrovirals during sex

Researchers have designed a novel suppository for HIV antiretroviral delivery using the seaweed extract carrageenan. Almost half of the antiretroviral drug tenofovir diffused out of the delivery mechanism within the first two hours in an in vitro study testing the product in water, vaginal simulant fluid and semen simulant fluid. 

Novel epitope for binding of HIV antibodies has major drug delivery implications

The discovery of a new HIV antibody highlights the need to create vaccines with trimeric delivery systems that resemble those found naturally, said Mark Connors, the research team's principal investigator and chief of the HIV-Specific Immunity Section.

BioTime enters academic collaborations to advance its hydrogel for vocal fold scarring

BioTime is entering into a partnership with the University of Wisconsin and Belgium's Louvain University to develop the company's hydrogel-based treatment for vocal fold scarring.

RNAi pipeline active as investors, patients wait for commercialization

A while ago, there was talk of a dreaded biotech bubble, and Novartis' decision to slam the breaks on its RNA interference research was making waves. But lately, the talk has turned positive on the promising yet unproven treatment paradigm, which utilizes RNAi to deliver gene-based therapy.

UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water

Creating the materials used for some of the most intricate nanostructures in drug delivery sometimes requires going back to the basics. In the case of researchers at the University of Oregon and the Berkeley Lab, this meant looking at the interaction between oil and water, developing nanosheets that could be used to compile delivery vehicles down the road.

Market research firm says needle-free vaccine delivery is the wave of the future

Expect more needle-free vaccines to come to market on the heels of the first approval of a needle-free delivery system for the inactivated flu vaccine, market research firm Frost & Sullivan says.

Artificial virus promises effective drug delivery and gene therapy

Dutch scientists from several different universities have collaborated to develop what could be useful as a drug delivery vehicle: an artificial virus with the ability to protect DNA and large molecules as they enter a cell.

UPDATED: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone?

Roche's announcement that it will acquire InterMune and its orally delivered drug pirfenidone has pushed the rare lung condition idiopathic pulmonary fibrosis (IPF) into the spotlight. Boehringer Ingelheim also has an oral drug for IPF on the horizon, but a little-known candidate for the condition has the potential to steal the big boys' thunder due to its differentiated delivery mechanism. 

Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition

Fresenius Kabi announced Aug. 26 that it has received approval of the Kabiven and Perikabiven, parenteral nutrition products in a three-chamber bag.

New antibody-drug conjugate research partnership announced

AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.

Organic nanoparticles offer 'complete package' against cancer: delivery and imaging

Nanoparticles come in many shapes and sizes, each specifically designed to play a precise role in cancer treatment. And now, researchers from UC Davis have created nanotechnology with the ability to perform multiple tasks and the ultimate goal of destroying tumors.

Vascular device drug delivery company surpasses VC goal

Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.